Hanall Biopharma (009420) - Total Liabilities
Based on the latest financial reports, Hanall Biopharma (009420) has total liabilities worth ₩44.17 Billion KRW (≈ $29.93 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Hanall Biopharma (009420) cash flow conversion to assess how effectively this company generates cash.
Hanall Biopharma - Total Liabilities Trend (2011–2024)
This chart illustrates how Hanall Biopharma's total liabilities have evolved over time, based on quarterly financial data. Check 009420 asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Hanall Biopharma Competitors by Total Liabilities
The table below lists competitors of Hanall Biopharma ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Caisse Regionale de Credit Agricole Mutuel du Languedoc
PA:CRLA
|
France | €30.13 Billion |
|
Shanghai Emperor of Cleaning Hi-Tech Co Ltd
SHG:603200
|
China | CN¥548.17 Million |
|
Suzhou Anjie Technology Co Ltd
SHE:002635
|
China | CN¥2.37 Billion |
|
A.F.P. Habitat
SN:HABITAT
|
Chile | CL$304.53 Billion |
|
Deterra Royalties Ltd
AU:DRR
|
Australia | AU$236.22 Million |
|
Graubuendner Kantonalbank
SW:GRKP
|
Switzerland | CHF33.30 Billion |
|
Kohl's Corporation
NYSE:KSS
|
USA | $10.21 Billion |
|
Cpi Fim SA
WAR:OPG
|
Poland | zł4.75 Billion |
Liability Composition Analysis (2011–2024)
This chart breaks down Hanall Biopharma's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Hanall Biopharma stock valuation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.01 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.28 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.22 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Hanall Biopharma's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Hanall Biopharma (2011–2024)
The table below shows the annual total liabilities of Hanall Biopharma from 2011 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩44.53 Billion ≈ $30.18 Million |
-16.81% |
| 2023-12-31 | ₩53.53 Billion ≈ $36.28 Million |
+18.44% |
| 2022-12-31 | ₩45.19 Billion ≈ $30.63 Million |
+29.18% |
| 2021-12-31 | ₩34.99 Billion ≈ $23.71 Million |
-9.97% |
| 2020-12-31 | ₩38.86 Billion ≈ $26.33 Million |
-23.76% |
| 2019-12-31 | ₩50.97 Billion ≈ $34.54 Million |
+12.29% |
| 2018-12-31 | ₩45.39 Billion ≈ $30.76 Million |
-21.06% |
| 2017-12-31 | ₩57.50 Billion ≈ $38.97 Million |
+182.22% |
| 2016-12-31 | ₩20.37 Billion ≈ $13.81 Million |
-7.01% |
| 2015-12-31 | ₩21.91 Billion ≈ $14.85 Million |
-47.03% |
| 2014-12-31 | ₩41.36 Billion ≈ $28.03 Million |
+8.20% |
| 2013-12-31 | ₩38.23 Billion ≈ $25.90 Million |
-16.18% |
| 2012-12-31 | ₩45.60 Billion ≈ $30.91 Million |
-16.71% |
| 2011-12-31 | ₩54.75 Billion ≈ $37.11 Million |
-- |
About Hanall Biopharma
Hanall Biopharma Co., Ltd., a pharmaceutical company, manufactures and sells pharmaceutical products in South Korea and internationally. The company offers prescription drugs and over-the-counter products for the treatment of diarrhea, prostatic hyperplasia, androgenetic alopecia, chronic renal failure, hypoparathyroidism, vitamin D-resistant rickets, osteomalacia, osteoporosis, prostate cancer, … Read more